Inhaled tigecycline therapy for pulmonary M. abscessus infections
吸入替加环素治疗肺部脓肿分枝杆菌感染
基本信息
- 批准号:10626051
- 负责人:
- 金额:$ 69.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-29 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AbscessAcuteAddressAdverse effectsAerosolsAnimal ModelAntibiotic ResistanceAntibioticsBacillusBiological AvailabilityBody FluidsC57BL/6 MouseCanis familiarisChronicClarithromycinClinicClinicalClinical effectivenessColoradoComplexDepositionDoseDrug ExposureDrug KineticsDrug or chemical Tissue DistributionDrynessEpitheliumExhibitsFiberFormulationFoundationsFrequenciesFutureGenus MycobacteriumGoalsGranulocyte-Macrophage Colony-Stimulating FactorHospitalsHourIn VitroInfectionInhalationInhalation Drug AdministrationInhalation TherapyIntravenousIntravenous infusion proceduresInvestigational New Drug ApplicationKnockout MiceLightLiquid substanceLungLung diseasesLung infectionsMacrolidesMaximum Tolerated DoseModelingMonitorMusMycobacterium abscessusNausea and VomitingOralOral AdministrationOrganOutcomePatientsPharmaceutical PreparationsPharmacotherapyPlasmaPowder dose formPredispositionProceduresPropertyQualifyingRattusRecommendationRegimenResearchResistanceRouteSafetySymptomsSystemTennesseeTestingTetracyclinesTherapeuticTherapeutic IndexTissuesToxicologyTreatment EfficacyTreatment ProtocolsUniversitiesVertebral columnWithdrawing Treatmentsanalogbacterial resistancebactericidecystic fibrosis mousecystic fibrosis patientseffective therapyefficacy evaluationefficacy testingepithelial Na+ channelflufollower of religion Jewishglycylcyclinehuman subjectimprovedin vitro Assayin vivointravenous administrationintravenous injectionliquid formulationmouse modelnon-tuberculosis mycobacteriaparticlepre-clinicalreconstitutionresistance mechanismside effectsubcutaneoussynergismtigecyclinetreatment duration
项目摘要
Summary
Mycobacterium abscessus (MAB) is a nontuberculous mycobacterium that causes chronic pulmonary infections
(pMAB) and patients with pre-existing lung disease (especially cystic fibrosis patients) have a predisposition to
pMAB. Due to MAB’s intrinsic antibiotic resistance, treatment is often complex and with low cure rates.
Tigecycline, a glycylcycline class antibiotic, demonstrates bactericidal effects against pMAB without eliciting
bacterial resistance mechanisms. For pMAB treatment, patients receive twice daily intravenous administration
of tigecycline during at least one month resulting in significant side effects and many patients withdraw from
treatment. Tigecycline has the potential to qualify as the first-line agent during therapy for pMAB and the
backbone for new combination regimens but to achieve its fullest therapeutic potential, we need to improve
tigecyclines ratio between efficacy and safety/tolerability, i.e. its therapeutic index. One approach to address this
challenge is to develop inhalational formulations of tigecycline that are easy to administer and are well
tolerated. In preliminary studies, GM-CSF KO mice with pMAB were treated by intrapulmonary aerosols of
tigecycline for 28 days. The pulmonary bacterial burden after full treatment duration showed that inhaled
tigecycline has high, dose-dependent efficacy, and is well tolerated. Here we hypothesize that aerosol delivery
of tigecycline is a viable therapeutic approach for pMAB. In Aim 1, to avoid the tigecycline requirements for
reconstitution, we will develop a dry powder formulation of tigecycline with well characterized aerodynamic
properties suitable for inhalation. Aim 2 will study the relationship between dose, dosing regimen and resulting
exposure of aerosols of tigecycline in different body fluids, organs and tissues. In particular, we will study the
dose-exposure relationship of inhaled versus intravenous tigecycline and its availability in plasma, lung,
abscesses and epithelial lining fluid. In Aim 3, we propose to test the efficacy, dose, dosing frequency, and
duration of inhaled tigecycline against pMAB using animal models. We propose using first the GM-CSF KO
murine model, subsequently, we will test the best regimen in b-ENac Tg mice with pMAB infection, as a
representative model for cystic fibrosis patients. The best regimen will be validated in mice infected with selected
clinical isolates from MAB clones 1 and 2 and isolates obtained from cystic fibrosis patients. Aim 4 will
determine efficacy of inhaled tigecycline in multidrug therapies. Mice with pMAB as in Aim 3 (with strain
#21 or clinical isolates) will be treated with binary or ternary combinations of inhaled tigecycline and
clarithromycin (oral), clofazimine (oral), bedaquiline (oral). These studies will be performed by a consortium of
experts located at Colorado State University, University of Tennessee, Research Triangle Institute and National
Jewish Hospital. Working together, we aim to provide an inhalational therapy regimen of tigecycline with well-
defined aerodynamic and PK properties and well characterized in vivo efficacy for future preclinical toxicology
studies in larger animal models, IND application, and ultimately administration to patients.
总结
结核分枝杆菌(MAB)是一种非结核分枝杆菌,可引起慢性肺部感染
(pMAB)和既存肺病患者(尤其是囊性纤维化患者)有以下倾向:
pMAB。由于MAB固有的抗生素耐药性,治疗通常很复杂,治愈率很低。
替加环素是一种甘氨酰环素类抗生素,对pMAB具有杀菌作用,
细菌耐药机制对于pMAB治疗,患者接受每日两次静脉内给药
替加环素治疗至少一个月,导致显著的副作用,许多患者退出治疗。
治疗替加环素有可能成为pMAB治疗期间的一线药物,
但为了实现其最大的治疗潜力,我们需要改进
有效性和安全性/耐受性之间的替格列汀比率,即其治疗指数。解决这一问题的一种方法是
挑战是开发易于给药且良好地
容忍。在初步研究中,用pMAB的GM-CSF KO小鼠通过以下肺内气雾剂处理:
替加环素28天。完整治疗期后的肺细菌负荷显示,吸入
替加环素具有高的剂量依赖性功效,并且耐受性良好。在这里,我们假设气溶胶输送
替加环素是pMAB的可行治疗方法。在目标1中,为了避免替加环素的要求,
重组,我们将开发一种替加环素的干粉制剂,
适合吸入的性质。目的2将研究剂量、给药方案和结果之间的关系。
替加环素气雾剂在不同体液、器官和组织中的暴露。我们会特别研究
吸入与静脉替加环素的剂量-暴露关系及其在血浆、肺
囊肿和上皮细胞衬液。在目标3中,我们建议测试疗效、剂量、给药频率和
使用动物模型的吸入替加环素对抗pMAB的持续时间。我们建议首先使用GM-CSF KO
小鼠模型,随后,我们将在pMAB感染的b-ENac Tg小鼠中测试最佳方案,
囊性纤维化患者的代表性模型。最佳方案将在感染选定的
来自MAB克隆1和2的临床分离物和从囊性纤维化患者获得的分离物。目标4将
确定吸入替加环素在多药治疗中的疗效。如在Aim 3中使用pMAB的小鼠(使用菌株
#21或临床分离株)将用吸入性替加环素和替加环素的二元或三元组合治疗。
克拉霉素(口服)、氯法齐明(口服)、贝达喹啉(口服)。这些研究将由一个财团进行,
位于科罗拉多州立大学、田纳西大学、三角研究所和国家
犹太医院我们共同努力,旨在提供一种替加环素吸入治疗方案,
明确的空气动力学和PK特性,并充分表征未来临床前毒理学的体内疗效
在更大的动物模型中的研究、IND应用以及最终对患者的施用。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Spray dried tigecycline dry powder aerosols for the treatment of Nontuberculous mycobacterial pulmonary infections.
喷雾干燥的tigecycline干粉气管可用于治疗非结核分枝杆菌肺部感染。
- DOI:10.1016/j.tube.2023.102306
- 发表时间:2023-03
- 期刊:
- 影响因子:0
- 作者:Maloney SE;Alshiraihi IM;Singh A;Stewart IE;Mariner Gonzalez J;Gonzalez-Juarrero M;Meibohm B;Hickey AJ
- 通讯作者:Hickey AJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mercedes Gonzalez-Juarrero其他文献
Mercedes Gonzalez-Juarrero的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mercedes Gonzalez-Juarrero', 18)}}的其他基金
Inhaled tigecycline therapy for pulmonary M. abscessus infections
吸入替加环素治疗肺部脓肿分枝杆菌感染
- 批准号:
10312329 - 财政年份:2021
- 资助金额:
$ 69.12万 - 项目类别:
Inhaled tigecycline therapy for pulmonary M. abscessus infections
吸入替加环素治疗肺部脓肿分枝杆菌感染
- 批准号:
10437923 - 财政年份:2021
- 资助金额:
$ 69.12万 - 项目类别:
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis
结核分枝杆菌多糖的剪裁修饰
- 批准号:
10490882 - 财政年份:2021
- 资助金额:
$ 69.12万 - 项目类别:
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis
结核分枝杆菌多糖的剪裁修饰
- 批准号:
10685409 - 财政年份:2021
- 资助金额:
$ 69.12万 - 项目类别:
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis
结核分枝杆菌多糖的剪裁修饰
- 批准号:
10387219 - 财政年份:2021
- 资助金额:
$ 69.12万 - 项目类别:
Vectra Polaris microscope imaging system
Vectra Polaris 显微镜成像系统
- 批准号:
10175807 - 财政年份:2021
- 资助金额:
$ 69.12万 - 项目类别:
Minipigs as animal model for infant TB and vaccine efficacy
小型猪作为婴儿结核病和疫苗功效的动物模型
- 批准号:
8810222 - 财政年份:2014
- 资助金额:
$ 69.12万 - 项目类别:
siRNA-nanoparticles host targeted immunotherapy for tuberculosis
siRNA 纳米颗粒作为结核病靶向免疫疗法的宿主
- 批准号:
8638299 - 财政年份:2014
- 资助金额:
$ 69.12万 - 项目类别:
Minipigs as animal model for infant TB and vaccine efficacy
小型猪作为婴儿结核病和疫苗功效的动物模型
- 批准号:
8684285 - 财政年份:2014
- 资助金额:
$ 69.12万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 69.12万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 69.12万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 69.12万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 69.12万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 69.12万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 69.12万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 69.12万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 69.12万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 69.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 69.12万 - 项目类别:
Standard Grant














{{item.name}}会员




